Clinical trials: Secondary Trauma
Pressure Sore, Pressure Ulcer
EmoLED Medical Device Treatment of Second and Third Stage Pressure Ulcers
The present clinical study aims to verify the effectiveness and safety of the blue light photobiomodulation therapy with EmoLED medical device in supporting the reparative process of the area of the second and third stage…
- Conditions
- Pressure Sore, Pressure Ulcer, Pressure Ulcers Stage III, Pressure Ulcers Stage II
- Trial name
- RISE_UP (NCT05130814)
- Testing
- blue light photobiomodulation, cleansing, hyaluronic acid gauze plus polyurethane foam
- Where
- Italy
- Volunteers
- 48 people
- Sponsor
- Emoled
Burn
A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-101 Clinical Trial
This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial(ALLO-ASC-BI-101) for 23 months.
- Trial name
- NCT03183622
- Testing
- ALLO-ASC-DFU
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- Anterogen Co., Ltd.
Primary Osteoarthritis, Secondary Osteoarthritis
Clinical and Radiological Outcomes of Medacta Shoulder System FR
This is a post-marketing surveillance on Medacta Shoulder System
- Conditions
- Primary Osteoarthritis, Secondary Osteoarthritis, Rotator Cuff Tear Arthropathy, Rheumatoid Arthritis Shoulder
- Trial name
- NCT05926622
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Medacta International SA
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral…
- Conditions
- Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin
- Trial name
- ON-5001 (NCT06022029)
- Testing
- ONM-501, Cemiplimab
- Where
- 16 sites in United States, Australia
- Volunteers
- 168 people
- Sponsor
- OncoNano Medicine, Inc.
Burn, Burn Wounds - Partial Thickness (2nd Degree)
Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns
This multicentre, randomised, double-blind, dose-finding, active- and placebo-controlled Phase II clinical trial will evaluate the safety, efficacy, pharmacokinetic profile, and immunogenicity of KJ101 for the debridement of deep…
- Trial name
- NCT07025408
- Testing
- KJ101, Chymotrypsin
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Shanghai Bao Pharmaceuticals Co., Ltd.
Bone Metastases
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases (lytic bone lesions from multiple myeloma) in subjects with advanced cancer and multiple…
- Trial name
- NCT00330759
- Testing
- Denosumab, Zoledronic Acid
- Volunteers
- 1,779 people
- Sponsor
- Amgen
Metastatic Castration-resistant Prostate Cancer
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
This is a master protocol designed to evaluate the safety and efficacy of investigational therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT04631601
- Testing
- Acapatamab, Enzalutamide, Abiraterone
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 55 people
- Sponsor
- Amgen
Prostate Cancer
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy.
- Trial name
- NCT04221542
- Testing
- AMG 509, Abiraterone, Enzalutamide
- Where
- 57 sites in United States, Australia and 8 more
- Volunteers
- 479 people
- Sponsor
- Amgen
Self-care, Compassion Satisfaction
Effect of Self-care Skill Education on the Compassionate Satisfaction and Compassionate Fatigue Among Clinical Nurses Clinical Nurses at HMC
The health of our nurses is perhaps the most important consideration for delivering excellent patient care. The passionate approach of nurses can lead to a lot of fatigue and stress among nurses.
- Conditions
- Self-care, Compassion Satisfaction, Compassion Fatigue, Educational Intervention
- Trial name
- NCT05983497
- Testing
- Self-Care Skill Educational Intervention
- Where
- Qatar
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Surgical Wound
A Prospective, Single-arm, Clinical Trial of Electrospun Fiber Matrix (Restrata) in the Treatment of Surgical Defects Secondary to Resection of Malignant Cutaneous Neoplasms
The goal of this observational prospective study is to evaluate wound healing outcomes in resection wounds resulting from surgical removal of cutaneous malignancies treated with a synthetic electrospun fiber matrix.
- Trial name
- NCT06578650
- Testing
- Synthetic Electrospun Fiber Matrix
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Acera Surgical, Inc.
Multiple Sclerosis, Muscle Spasticity
Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.
This study is being conducted to compare the impact of somnolence (sleepiness) on cognition (awareness) as well as the safety and effectiveness of tizanidine hydrochloride capsules versus Zanaflex® (tizanidine hydrochloride…
- Conditions
- Multiple Sclerosis, Muscle Spasticity, Spinal Cord Injury, Stroke
- Trial name
- NCT00047580
- Testing
- tizanidine hydrochloride capsule
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Elan Pharmaceuticals
Burn
A Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Deep Second-degree Burn Wound
This is a phase I study to evaluate the safety of ALLO-ASC-DFU for the treatment of deep second-degree burn wound patients. ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells.
- Trial name
- NCT02394873
- Testing
- ALLO-ASC-DFU
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- Anterogen Co., Ltd.
Burn Injury, Burn Scar
Tissue Quality of Integra vs. BTM Treated Burns
An observational analysis of Integra-treated burns and Novosorb Biodegradable Temporizing Matrix (BTM)-treated burns will be undertaken 12-36 months post final skin graft application by retrospectively analyzing the patient's…
- Conditions
- Burn Injury, Burn Scar, Burn Wounds - Partial Thickness (2nd Degree), Skin Grafting
- Trial name
- NCT06760611
- Sponsor
- Integra LifeSciences Corporation
Burns, Wound Healing
A Clinical Investigation to Evaluate Efficacy of Mepitel Ag in Partial Thickness Second Degree Burns
Approximately 55-65 subjects from 3-6 sites suffering from a burn injury covering 1-25% Total Body Surface Area (TBSA) will be evaluated providing they fulfill all inclusion and none of the exclusion criteria and have given a…
- Trial name
- NCT01636362
- Testing
- Mepitel Ag
- Where
- 6 sites in United States
- Volunteers
- 45 people
- Sponsor
- Molnlycke Health Care AB
Bone Metastases
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases in men with hormone-refractory prostate cancer
- Trial name
- NCT00321620
- Testing
- zoledronic acid, denosumab
- Volunteers
- 1,904 people
- Sponsor
- Amgen
Primary Osteoarthritis, Secondary Osteoarthritis
Prospective Study for the Evaluation of the Cementless Anatomic Femoral Stem Minimax -Launay
This is a post-marketing surveillance on MiniMAX Stem
- Conditions
- Primary Osteoarthritis, Secondary Osteoarthritis, Traumatic Arthritis, Rheumatoid Arthritis
- Trial name
- NCT06012656
- Testing
- MiniMAX
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Medacta International SA
Burn Wounds - Partial Thickness (2nd Degree)
Field Shield Wound Dressing Study
This study is to compare the Field Shield Wound Dressing (FSWD) as a treatment for burn wounds to a standard of care burn wound dressing to evaluate healing, infection, pain/discomfort, and deepening of wound over time.
- Trial name
- NCT07337616
- Testing
- Field Shield Wound Dressing, Silverlon
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- KeriCure Medical
Acute Burns
Using Autologous Platelet Rich Plasma (PRP) Gel to Treat Deep 2nd and 3rd Degree Burns
This study will demonstrate the safety of the application of autologous platelet rich plasma (PRP) gel following excision and autologous skin grafting of acute deep 2nd and 3rd degree burns.
- Trial name
- NCT01843686
- Testing
- Magellan®
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Arteriocyte, Inc.
Femur Neck Fracture
Second Study of the Effect of Teriparatide on Hip Fracture Healing
The purpose of this study is to see whether teriparatide, given for 6 months versus placebo, will improve the healing of hip (femoral neck) fractures that are repaired during surgery using certain types of orthopedic screws.
- Trial name
- NCT01473602
- Testing
- Teriparatide, Calcium supplementation, Vitamin D supplementation
- Where
- 75 sites in United States, Belgium and 12 more
- Volunteers
- 39 people
- Sponsor
- Eli Lilly and Company
Burns, Burns Second Degree
CellMist™ Autologous Cells to Treat Deep Second-Degree Burns
The overall purpose of this study is to evaluate the safety of the CellMist™ System in the treatment of deep second degree burns (II°B) in a prospective, multicenter, feasibility pilot study.
- Conditions
- Burns, Burns Second Degree, Burns Deep Second Degree
- Trial name
- CELLMIST1 (NCT04890574)
- Testing
- CellMist™ System
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- RenovaCare, Inc